OBJECTIVES: To assess the predictive value of neuropsychologic profiles, at diagnosis, for mortality in incident Alzheimer disease (AD). BACKGROUND: Rate of AD progression varies significantly across individuals for reasons that are not well understood. Several studies have linked rapid decline with disproportionately impaired executive functioning, presumably reflecting greater impairment of frontal networks. To the extent that differential neuropsychologic profiles reflect various neuropathologic presentations of AD, such profiles may inform survival estimates early in the disease. METHODS: Five neuropsychologic indices were used to characterize performance in 161 individuals at diagnosis of AD during a 15-year, longitudinal, primarily community-based study. RESULTS: Fifty-two percent of participants reached the mortality end point with a median survival of 5.52 years (95% confidence interval, 4.41-6.63). Cox proportional hazards analyses indicated that older age at diagnosis was associated with higher risk of mortality (risk ratios, 1.08; 95% confidence interval, 1.04-1.12) whereas Hispanic ethnicity predicted lower mortality [0.22 (0.09-0.55)]. Controlling for these 2 demographic variables, higher verbal fluency scores at diagnosis predicted lower mortality [0.69 (0.49-0.96)]. CONCLUSIONS: Disproportionate impairment of both category and letter fluency at the earliest stages of AD predicts mortality. The prognostic value of these tests may derive from their general psychometric properties, or may reflect the measures' sensitivity to an early or critical level of compromise to frontal networks.
OBJECTIVES: To assess the predictive value of neuropsychologic profiles, at diagnosis, for mortality in incident Alzheimer disease (AD). BACKGROUND: Rate of AD progression varies significantly across individuals for reasons that are not well understood. Several studies have linked rapid decline with disproportionately impaired executive functioning, presumably reflecting greater impairment of frontal networks. To the extent that differential neuropsychologic profiles reflect various neuropathologic presentations of AD, such profiles may inform survival estimates early in the disease. METHODS: Five neuropsychologic indices were used to characterize performance in 161 individuals at diagnosis of AD during a 15-year, longitudinal, primarily community-based study. RESULTS: Fifty-two percent of participants reached the mortality end point with a median survival of 5.52 years (95% confidence interval, 4.41-6.63). Cox proportional hazards analyses indicated that older age at diagnosis was associated with higher risk of mortality (risk ratios, 1.08; 95% confidence interval, 1.04-1.12) whereas Hispanic ethnicity predicted lower mortality [0.22 (0.09-0.55)]. Controlling for these 2 demographic variables, higher verbal fluency scores at diagnosis predicted lower mortality [0.69 (0.49-0.96)]. CONCLUSIONS: Disproportionate impairment of both category and letter fluency at the earliest stages of AD predicts mortality. The prognostic value of these tests may derive from their general psychometric properties, or may reflect the measures' sensitivity to an early or critical level of compromise to frontal networks.
Authors: Deborah A Levine; Andrzej T Galecki; Kenneth M Langa; Frederick W Unverzagt; Mohammed U Kabeto; Bruno Giordani; Mary Cushman; Leslie A McClure; Monika M Safford; Virginia G Wadley Journal: Hypertension Date: 2019-02 Impact factor: 10.190
Authors: Deborah A Levine; Andrzej T Galecki; Kenneth M Langa; Frederick W Unverzagt; Mohammed U Kabeto; Bruno Giordani; Virginia G Wadley Journal: JAMA Date: 2015-07-07 Impact factor: 56.272
Authors: Jeff Schaffert; Christian LoBue; Linda S Hynan; John Hart; Heidi Rossetti; Anne R Carlew; Laura Lacritz; Charles L White; C Munro Cullum Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.472
Authors: Steven H Ferris; Frederick A Schmitt; Judith Saxton; Sharon Richardson; Joan Mackell; Yijun Sun; Yikang Xu Journal: Alzheimers Res Ther Date: 2011-06-20 Impact factor: 6.982
Authors: Deborah A Levine; Alden L Gross; Emily M Briceño; Nicholas Tilton; Mohammed U Kabeto; Stephanie M Hingtgen; Bruno J Giordani; Jeremy B Sussman; Rodney A Hayward; James F Burke; Mitchell S V Elkind; Jennifer J Manly; Andrew E Moran; Erin R Kulick; Rebecca F Gottesman; Keenan A Walker; Yuichiro Yano; Darrell J Gaskin; Stephen Sidney; Kristine Yaffe; Ralph L Sacco; Clinton B Wright; Veronique L Roger; Norrina Bai Allen; Andrzej T Galecki Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 29.907